TRPV2: A Key Player in Myelination Disorders of the Central Nervous System

dc.contributor.authorEnrich Bengoa, Jennifer
dc.contributor.authorManich Raventós, Gemma
dc.contributor.authorValente, Tony
dc.contributor.authorSanchez Molina, Paula
dc.contributor.authorAlmolda, Beatriz
dc.contributor.authorSolà i Subirana, Carme
dc.contributor.authorSaura Martí, Josep
dc.contributor.authorGonzález, Berta
dc.contributor.authorCastellano, Bernardo
dc.contributor.authorPerálvarez Marín, Alex
dc.date.accessioned2022-05-17T17:00:30Z
dc.date.available2022-05-17T17:00:30Z
dc.date.issued2022-03-25
dc.date.updated2022-05-17T17:00:30Z
dc.description.abstractTransient potential receptor vanilloid 2 (TRPV2) is widely expressed through the nervous system and specifically found in neuronal subpopulations and some glial cells. TRPV2 is known to be sensitized by methionine oxidation, which results from inflammation. Here we aim to characterize the expression and regulation of TRPV2 in myelination pathologies, such as hypomyelination and demyelination. We validated the interaction between TRPV2 and its putative interactor Opalin, an oligodendrocyte marker, in mixed glial cultures under pro- and anti-inflammatory conditions. Then, we characterized TRPV2 time-course expression in experimental animal models of hypomyelination (jimpy mice) and de-/remyelination (cuprizone intoxication and experimental autoimmune encephalomyelitis (EAE)). TRPV2 showed upregulation associated with remyelination, inflammation in cuprizone and EAE models, and downregulation in hypomyelinated jimpy mice. TRPV2 expression was altered in human samples of multiple sclerosis (MS) patients. Additionally, we analyzed the expression of methionine sulfoxide reductase A (MSRA), an enzyme that reduces oxidated methionines in TRPV2, which we found increased in inflammatory conditions. These results suggest that TRPV2 may be a key player in myelination in accordance with the recapitulation hypothesis, and that it may become an interesting clinical target in the treatment of demyelination disorders.
dc.format.extent24 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec723053
dc.identifier.issn1661-6596
dc.identifier.pmid35408977
dc.identifier.urihttps://hdl.handle.net/2445/185670
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijms23073617
dc.relation.ispartofInternational Journal of Molecular Sciences, 2022, vol. 23, num. 7, p. 3617
dc.relation.urihttps://doi.org/10.3390/ijms23073617
dc.rightscc-by (c) Enrich Bengoa, Jennifer et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Biomedicina)
dc.subject.classificationMalalties del sistema nerviós central
dc.subject.classificationMielina
dc.subject.classificationEstrès oxidatiu
dc.subject.classificationEsclerosi múltiple
dc.subject.classificationCanals iònics
dc.subject.otherCentral nervous system diseases
dc.subject.otherMyelin sheath
dc.subject.otherOxidative stress
dc.subject.otherMultiple sclerosis
dc.subject.otherIon channels
dc.titleTRPV2: A Key Player in Myelination Disorders of the Central Nervous System
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
723053.pdf
Mida:
4.04 MB
Format:
Adobe Portable Document Format